Real World Adherence to HIV PrEP in Serodiscordant African Couples

现实世界中血清不一致的非洲夫妇对 HIV PrEP 的遵守情况

• 批准号: 9085371
• 负责人: Jessica Elizabeth Haberer
• 金额: $ 59.41万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-06-04 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9085371
• 关键词: AIDS prevention; Acute; Address; Adherence; Africa South of the Sahara; African; Behavior; Behavior Therapy; Clinical Trials; Consensus; Cost Effectiveness Analysis; Counseling; Couples; Data; Dose; Effectiveness; Electronics; Emotional Bonds; Epithelium; Event; Fertility; Frequencies; Funding; HIV; HIV Infections; HIV Seropositivity; Health; Health Care Costs; Heterogeneity; Heterosexuals; Individual; Infection; Intervention; Interview; Investigation; Investments; Kenya; Link; Measurement; Measures; Modeling; Monitor; Motivation; Oral; Participant; Pattern; Persons; Pharmaceutical Preparations; Phase III Clinical Trials; Placebos; Prevention strategy; Prophylactic treatment; Protocols documentation; Public Health; Recruitment Activity; Reporting; Research; Research Personnel; Risk; Sampling; Sex Behavior; Statistical Data Interpretation; Surveys; System; Tenofovir; Text; Theoretical model; Time; Trust; Uganda; United States National Institutes of Health; Vagina; Visit; Woman; Work; antiretroviral therapy; base; clinical epidemiology; cost; cost effective; cost effectiveness; design; emtricitabine; experience; high risk; improved; innovation; mathematical model; member; men who have sex with men; novel; open label; pharmacokinetic model; pill; scale up; sexual relationship; transmission process

DESCRIPTION (provided by applicant): Oral pre-exposure prophylaxis (PrEP) against HIV infection has demonstrated efficacy in men who have sex with men, serodiscordant couples, and young heterosexuals; however, efficacy was not shown in two studies of women. Lack of adherence is the leading hypothesis for these discrepant findings. Adherence outside of rigorous clinical trials is unknown and is essential to know in order to determine whether PrEP will be an effective public health strategy. The proposed study will determine if HIV-uninfected people in serodiscordant couples outside a clinical trial will adhere adequately enough to PrEP to be protected against HIV transmission. Approach: This study builds on our experience conducting the Adherence Sub-study within the Partners PrEP Study (a phase III clinical trial of tenofovir and emtricitabine/tenofovir PrEP) and will be integrated into a recently funded study of a public health delivery model of antiretroviral therapy-based HIV prevention strategies involving 500 serodiscordant couples in Uganda and Kenya (R01MH095507, PI: Baeten). Our Specific Aims are a follows: 1) Assess the level, trajectory, and correlates of PrEP adherence in research-naive discordant couples receiving PrEP in a public health delivery model with adherence counseling practical for scale-up; 2) Determine the relationship between patterns of adherence and risk exposure outside of a clinical trial; and 3) Determine if the level and patterns of real world adherence and risk exposure determined in Aims 1 and 2 substantially alter current estimates of PrEP effectiveness and cost-effectiveness. Innovation: We will: 1) characterize PrEP adherence in serodiscordant couples recruited into a demonstration project of PrEP delivery involving limited adherence counseling that is practical for scale-up settings; 2) use a novel conceptual framework to understand PrEP adherence behavior; 3) use text message reports of sexual behavior combined with electronic adherence monitoring to characterize temporal patterns of sexual exposure and PrEP adherence; and 4) develop models of the tenofovir drug concentration-time relationship, using prospectively collected samples, which can be used to determine which patterns of adherence are likely adequate for protection against HIV infection. Investigators: Dr. Jessica Haberer is a new investigator with significant experience studying adherence to antiretroviral therapy and PrEP in sub-Saharan Africa. Her team includes expertise in clinical epidemiology (Drs. Jared Baeten and Connie Celum), adherence measurement (Dr. David Bangsberg), qualitative analysis (Dr. Norma Ware), tenofovir pharmacokinetic modeling (Drs. Craig Hendrix and Ayyappa Chaturvedula), statistical analysis (Dr. Deborah Donnell), cost-effective modeling (Dr. Tim Hallett), and sub-Saharan African research experience (Drs. Nelly Mugo and Elly Katabira).

描述(由申请人提供)：口服暴露前预防(PrEP)预防艾滋病毒感染在男男性行为者、血清不一致的夫妇和年轻的异性恋者中显示出有效性；然而，在两项针对女性的研究中没有显示出有效性。缺乏坚持是这些不一致发现的主要假设。在严格的临床试验之外的依从性是未知的，为了确定PrEP是否将是一种有效的公共卫生策略，了解这一点是必不可少的。这项拟议的研究将确定在临床试验之外的血清不一致夫妇中未感染艾滋病毒的人是否会充分遵守PrEP，以防止艾滋病毒传播。方法：这项研究建立在我们在合作伙伴PrEP研究(替诺福韦和恩曲他滨/替诺福韦PrEP的第三阶段临床试验)内进行依从性分研究的经验的基础上，并将被纳入最近资助的一项关于基于抗逆转录病毒治疗的艾滋病毒预防策略的公共卫生提供模式的研究，涉及乌干达和肯尼亚500对血清不一致的夫妇(R01MH095507，PI：Baeten)。我们的具体目标如下：1)在研究中评估PrEP依从性的水平、轨迹和相关性-在公共卫生提供模式中接受PrEP的幼稚不协调夫妇，以及可用于扩大规模的依从性咨询；2)确定依从性模式与临床试验外风险暴露之间的关系；以及3)确定目标1和2中确定的真实世界依从性和风险暴露的水平和模式是否会大幅改变目前对PrEP有效性和成本效益的估计。创新：我们将：1)描述在PrEP交付示范项目中招募的血清不一致夫妇的PrEP依从性，该项目涉及适用于扩大环境的有限依从性咨询；2) 使用新的概念框架来理解PrEP依从性行为；3)使用短信报告结合电子依从性监测来表征性行为和PrEP依从性的时间模式；以及4)使用预期收集的样本，建立替诺福韦药物浓度-时间关系的模型，这些模型可用于确定哪些依从性模式可能足以预防艾滋病毒感染。研究人员：Jessica Haberer博士是一名新的研究人员，在撒哈拉以南非洲地区研究抗逆转录病毒治疗和PrEP的依从性方面拥有丰富的经验。她的团队包括临床流行病学(Jared Baeten博士和Connie Celum博士)、依从性测量(David Bunsberg博士)、定性分析(Norma Ware博士)、替诺福韦药代动力学建模(Craig Hendrix和Ayappa Chaturvedula博士)、统计分析(Deborah Donnell博士)、成本效益建模(Tim Hallett博士)以及撒哈拉以南非洲研究经验(Nelly Mugo和Elly Katabira博士)。